Weizhi He

Weizhi He

Auto-generated profile, based on publicly available information

Weizhi He

State Key Laboratory of Oncogenes and Related Genes, Stem Cell Research Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
WHWeizhi He
Weizhi He
JWJinghua Wu
Jinghua Wu
JSJuanjuan Shi
Juanjuan Shi
YHYan-Miao Huo
Yan-Miao Huo
WDWentao Dai
Wentao Dai
JXJing Xue
Jing Xue
Chronic inflammation is a feature of pancreatic cancer, but little is known about how immune cells or immune cell–related signals affect pancreatic cancer stemness and development. Our previous work showed that IL22/IL22RA1 plays a vital role in acute and chronic pancreatitis progression by mediating cross-talk between immune cells and acinar cells or stellate cells, respectively. Here, we find IL22RA1 is highly but heterogeneously expressed in pancreatic cancer cells, with high expression associated with poor prognosis of patients with pancreatic cancer. The IL22RA1hi population from pancreatic cancer harbored higher stemness potential and tumorigenicity. Notably, IL22 promoted pancreatic cancer stemness via IL22RA1/STAT3 signaling, establishing the mechanism of regulation of cancer stemness by microenvironmental factors. Moreover, STAT3 was indispensable for the maintenance of IL22RA1hi cells. Overall, these findings provide a therapeutic strategy for patients with PDAC with high expression of IL22RA1. Significance: IL22RA1/STAT3 signaling enhances stemness and tumorigenicity in pancreatic cancer. Cancer Res; 78(12); 3293–305. ©2018 AACR.

31 March 2023
Verified
Other
Open access
WHWeizhi He
Weizhi He
JWJinghua Wu
Jinghua Wu
JSJuanjuan Shi
Juanjuan Shi
YHYan-Miao Huo
Yan-Miao Huo
WDWentao Dai
Wentao Dai
JXJing Xue
Jing Xue
Chronic inflammation is a feature of pancreatic cancer, but little is known about how immune cells or immune cell–related signals affect pancreatic cancer stemness and development. Our previous work showed that IL22/IL22RA1 plays a vital role in acute and chronic pancreatitis progression by mediating cross-talk between immune cells and acinar cells or stellate cells, respectively. Here, we find IL22RA1 is highly but heterogeneously expressed in pancreatic cancer cells, with high expression associated with poor prognosis of patients with pancreatic cancer. The IL22RA1hi population from pancreatic cancer harbored higher stemness potential and tumorigenicity. Notably, IL22 promoted pancreatic cancer stemness via IL22RA1/STAT3 signaling, establishing the mechanism of regulation of cancer stemness by microenvironmental factors. Moreover, STAT3 was indispensable for the maintenance of IL22RA1hi cells. Overall, these findings provide a therapeutic strategy for patients with PDAC with high expression of IL22RA1.Significance: IL22RA1/STAT3 signaling enhances stemness and tumorigenicity in pancreatic cancer. Cancer Res; 78(12); 3293–305. ©2018 AACR.

31 March 2023
Verified
Other
Open access
WHWeizhi He
Weizhi He
JWJinghua Wu
Jinghua Wu
JSJuanjuan Shi
Juanjuan Shi
YHYan-Miao Huo
Yan-Miao Huo
WDWentao Dai
Wentao Dai
JXJing Xue
Jing Xue
Figure S1.Flow cytometry analysis of IL-22RA1 expression among PDAC; Figure S2. The correlation analyses between IL-22RA1 and CSCs Figure S3. IL-22RA1hi pancreatic cancer cells have CSCs properties Figure S4. IL-22RA1hi pancreatic cancer cells express higher EMT markers FigureS5. IL-22 promotes stemness of pancreatic cancer cells FigureS6. IL-6 activates STAT3, but unable to promote stemness of PDACs Figure S7. Dot1L is not involved in IL-22 induced stemness of PDACs Table S1. Quantitative real-time PCR and ChIP primers TableS2&3. The co-relationship between IL-22RA1 expression and PDAC patients characteristics

31 March 2023
Verified
Other
Open access
WHWeizhi He
Weizhi He
JWJinghua Wu
Jinghua Wu
JSJuanjuan Shi
Juanjuan Shi
YHYan-Miao Huo
Yan-Miao Huo
WDWentao Dai
Wentao Dai
JXJing Xue
Jing Xue
Chronic inflammation is a feature of pancreatic cancer, but little is known about how immune cells or immune cell–related signals affect pancreatic cancer stemness and development. Our previous work showed that IL22/IL22RA1 plays a vital role in acute and chronic pancreatitis progression by mediating cross-talk between immune cells and acinar cells or stellate cells, respectively. Here, we find IL22RA1 is highly but heterogeneously expressed in pancreatic cancer cells, with high expression associated with poor prognosis of patients with pancreatic cancer. The IL22RA1hi population from pancreatic cancer harbored higher stemness potential and tumorigenicity. Notably, IL22 promoted pancreatic cancer stemness via IL22RA1/STAT3 signaling, establishing the mechanism of regulation of cancer stemness by microenvironmental factors. Moreover, STAT3 was indispensable for the maintenance of IL22RA1hi cells. Overall, these findings provide a therapeutic strategy for patients with PDAC with high expression of IL22RA1.Significance: IL22RA1/STAT3 signaling enhances stemness and tumorigenicity in pancreatic cancer. Cancer Res; 78(12); 3293–305. ©2018 AACR.

31 March 2023
Verified
Other
Open access
WHWeizhi He
Weizhi He
JWJinghua Wu
Jinghua Wu
JSJuanjuan Shi
Juanjuan Shi
YHYan-Miao Huo
Yan-Miao Huo
WDWentao Dai
Wentao Dai
JXJing Xue
Jing Xue
Figure S1.Flow cytometry analysis of IL-22RA1 expression among PDAC; Figure S2. The correlation analyses between IL-22RA1 and CSCs Figure S3. IL-22RA1hi pancreatic cancer cells have CSCs properties Figure S4. IL-22RA1hi pancreatic cancer cells express higher EMT markers FigureS5. IL-22 promotes stemness of pancreatic cancer cells FigureS6. IL-6 activates STAT3, but unable to promote stemness of PDACs Figure S7. Dot1L is not involved in IL-22 induced stemness of PDACs Table S1. Quantitative real-time PCR and ChIP primers TableS2&3. The co-relationship between IL-22RA1 expression and PDAC patients characteristics